Elyse Stock
Director/Miembro de la Junta en Areteia Therapeutics, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Jorge Bartolome | M | - |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Ian Read | M | 71 |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Clifford Bechtold | M | - | 7 años | |
Paloma Moraleda | F | - | 2 años | |
Gastón Ortega | M | - | 2 años | |
Paul Berns | M | 57 |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Adam Koppel | M | 54 |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Michael E. Bozik | M | - |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Benjamin Gomez | M | - |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Melissa Beiner | M | - | 7 años | |
Shuai Li | M | - | 7 años | |
Jennifer Porcelli | F | - | 2 años | |
BUTTS STEVE | M | - |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
George Clark | M | - | 4 años | |
Julia Gregory | F | 71 | 5 años | |
Gregory Bailey | M | 68 | 8 años | |
Declan Doogan | M | 72 | 8 años | |
Vladimir Coric | M | 53 | 7 años | |
John Childs | M | 81 | 8 años | |
Douglas G. Gray | M | - | - | |
John Tilton | M | 56 | 6 años | |
Kimberly Gentile | F | 56 | 8 años | |
Charles Conway | M | 62 | 5 años | |
James Engelhart | M | 60 | 5 años | |
Irina Antonijevic | M | 59 | - | |
Kishan Mehta | M | 38 | 1 años | |
Robert Repella | M | 65 | 2 años | |
Michael Heffernan | M | 59 | 2 años | |
Eric Aguiar | M | 62 | 4 años | |
Matthew Buten | M | 62 | 1 años | |
Robert Hugin | M | 69 | 2 años | |
William Jones | M | 60 | 3 años | |
Scott Phillips | M | - | 1 años | |
Albert Cha | M | 51 | 1 años | |
St John McGrath | M | - | 5 años | |
Robert Croop | M | - | - | |
Matthew Hubbard | M | - | 3 años | |
Loren Aguiar | M | - | 5 años | |
Matthew DeLawder | M | - | 5 años | |
Jenny Strauss | F | - | 4 años | |
David Saunders | M | - | 3 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 7 | 17.07% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Elyse Stock
- Red Personal